Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2014

View Archived Issues

Research sheds light on HMG-1 expression in MS brain tissue

Oxford BioMedica and Novartis expand LentiVector collaboration

Researchers at Edison Pharmaceuticals disclose new agents for Friedreich's ataxia

New aldehyde compounds disclosed for sickle cell disease and other disorders

Chinese group patents new ALK inhibitors for cancer

Novel viral entry inhibitors synthesized for DENV infection

Merck & Co. divulges new JAK inhibitors

First-in-human results for BI-655066 in psoriasis

Omniox receives Wellcome Trust grant to develop oxygen carrier OMX-4.80 for cancer

Ebola vaccine studied in healthcare workers in Mali

BCX-4161 shows efficacy and safety in OPuS-1 trial

Deciphera receives orphan drug designation for gastrointestinal stromal tumor agent

Novel platelet protein biochip used to identify AD biomarkers

FDA approves Harvoni for hepatitis C

FDA approves netupitant/palonosetron combination for CINV

World Thrombosis Day: Advocating for more effective prevention, diagnosis and treatment options

Prosensa starts rolling NDA submission for drisapersen

Endo to acquire Auxilium Pharmaceuticals

Biotron reports promising data from phase II trial of BIT-225 in HCV

FDA approves Bard's paclitaxel-coated angioplasty balloon

Galecto Biotech initiates phase I/II trial of galectin-3 inhibitor for IPF

Biogen Idec files MAA for Elocta in Europe

Impax signs definitive agreement to acquire Tower Holdings and Lineage Therapeutics

Reata starts trial of RTA-408 and ipilimumab in melanoma

Orexo applies to FDA to expand Zubsolv label to include initiation of opioid dependence therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...